Tocolysis for in utero Surgery: Atosiban Performs Distinctly Better than Magnesium Sulfate.

What Was Tested

This clinical trial looks at Vitamin D, K2, Magnesium and Zinc.

To compare tocolysis with magnesium sulfate versus atosiban regarding the occurrence of short-term preterm labor and maternal side effects during and after open fetal myelomeningocele (MMC) repair.

Who Took Part

The age groups tagged for this paper are adults, women only.

How the Study Was Run

A prospective nonrandomized cohort study was performed including 30 fetal MMC cases.

The first 15 cases (group 1) received magnesium sulfate according to the MOMS protocol.

In the following 15 cases (group 2), magnesium sulfate was substituted by atosiban.

Chorioamniotic membrane separation (CMS), premature prelabor rupture of the fetal membranes (PPROM), preterm delivery <3 weeks after fetal MMC repair, and maternal complications due to the tocolytic medication were the major endpoints.

What Was Measured

PubMed files the paper under topics including Fetal Therapies, Magnesium Sulfate, Tocolysis, Tocolytic Agents and Vasotocin.

The authors tagged it with the keywords Atosiban, Fetal myelomeningocele repair, Fetal surgery and In utero surgery.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Fetal diagnosis and therapy), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.